CA2740566C - Peptide adjuvants - Google Patents

Peptide adjuvants Download PDF

Info

Publication number
CA2740566C
CA2740566C CA2740566A CA2740566A CA2740566C CA 2740566 C CA2740566 C CA 2740566C CA 2740566 A CA2740566 A CA 2740566A CA 2740566 A CA2740566 A CA 2740566A CA 2740566 C CA2740566 C CA 2740566C
Authority
CA
Canada
Prior art keywords
seq
peptide
antigen
adjuvant
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2740566A
Other languages
English (en)
French (fr)
Other versions
CA2740566A1 (en
Inventor
Shawn Babiuk
Darwyn Kobasa
Gary Kobinger
Ami Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ministry of Health and Long Term Care
Original Assignee
Ministry of Health and Long Term Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ministry of Health and Long Term Care filed Critical Ministry of Health and Long Term Care
Publication of CA2740566A1 publication Critical patent/CA2740566A1/en
Application granted granted Critical
Publication of CA2740566C publication Critical patent/CA2740566C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2740566A 2008-11-28 2009-11-30 Peptide adjuvants Expired - Fee Related CA2740566C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11853308P 2008-11-28 2008-11-28
US61/118,533 2008-11-28
PCT/CA2009/001707 WO2010060208A1 (en) 2008-11-28 2009-11-30 Peptide adjuvants

Publications (2)

Publication Number Publication Date
CA2740566A1 CA2740566A1 (en) 2010-06-03
CA2740566C true CA2740566C (en) 2017-11-28

Family

ID=42225170

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2740566A Expired - Fee Related CA2740566C (en) 2008-11-28 2009-11-30 Peptide adjuvants

Country Status (8)

Country Link
US (2) US8404243B2 (enExample)
EP (2) EP2987502B1 (enExample)
JP (2) JP5656857B2 (enExample)
AU (2) AU2009319667B2 (enExample)
CA (1) CA2740566C (enExample)
ES (2) ES2615120T3 (enExample)
NZ (1) NZ593200A (enExample)
WO (1) WO2010060208A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012153337A2 (en) * 2011-05-11 2012-11-15 Technion Research & Development Foundation Ltd. Anti-microbial peptides and uses of same
US10004811B2 (en) 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
CA3100236A1 (en) * 2020-11-20 2022-05-20 Universite Laval Severe acute respiratory syndrome coronavirus dna vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
GB9425582D0 (en) * 1994-12-19 1995-02-15 Iaf Biochem Int Peptides having immunomodulatory activity
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US7371837B2 (en) * 2004-07-21 2008-05-13 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof

Also Published As

Publication number Publication date
US9211325B2 (en) 2015-12-15
EP2370100B1 (en) 2015-04-08
US8404243B2 (en) 2013-03-26
AU2016201589B2 (en) 2016-11-24
JP5656857B2 (ja) 2015-01-21
AU2016201589A1 (en) 2016-03-31
WO2010060208A1 (en) 2010-06-03
AU2009319667A1 (en) 2011-06-23
EP2370100A4 (en) 2013-05-22
EP2370100A1 (en) 2011-10-05
JP2012509906A (ja) 2012-04-26
JP5901084B2 (ja) 2016-04-06
US20130323285A1 (en) 2013-12-05
EP2987502B1 (en) 2016-11-09
US20110305720A1 (en) 2011-12-15
CA2740566A1 (en) 2010-06-03
ES2541443T3 (es) 2015-07-20
JP2015091811A (ja) 2015-05-14
EP2987502A1 (en) 2016-02-24
AU2009319667B2 (en) 2016-03-03
NZ593200A (en) 2012-10-26
ES2615120T3 (es) 2017-06-05

Similar Documents

Publication Publication Date Title
JP2016501850A (ja) 口蹄疫（ｆｍｄ）に対する合成ペプチドベースの緊急ワクチン
Heal et al. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids
JP2010506926A (ja) Ｉｉ−Ｋｅｙ増強ワクチンの効力
TWI754817B (zh) 以人工混雜ｔ輔助細胞抗原決定位以有限度的ｔ細胞發炎反應促進目標抗體的生產
AU2016201589B2 (en) Peptide adjuvants
Yin et al. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine
AU2011360572B2 (en) Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
Yoon et al. Comparison of responses elicited by immunization with a Legionella species common lipoprotein delivered as naked DNA or recombinant protein
Moisa et al. Synthetic peptide vaccines
CN113476600B (zh) Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物
Moisa et al. Synthetic peptide vaccines
Arnon et al. Peptide-based synthetic recombinant vaccines with anti-viral efficacy
KR20200032169A (ko) 말라리아 백신
WO2018085488A1 (en) Universal mammalian influenza vaccine
JP7239203B2 (ja) ＩｇＥ媒介型アレルギー性疾患治療のための、膜結合型ＩｇＥを標的とするペプチド免疫原及びそれらの製剤
CN121342933A (zh) 冠状病毒s蛋白突变体及其应用
Robinson Horizons in Chemical Immunology–Approaches to Synthetic Vaccine Design
HK40045220A (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
Ben-Yedidia A peptide-based vaccine against influenza
HK1192455A (en) Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140929

MKLA Lapsed

Effective date: 20181130